MannKind Corporation (NASDAQ:MNKD) VP David Thomson unloaded 133,000 shares of MannKind stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $9.95, for a total value of $1,323,350.00. Following the transaction, the vice president now directly owns 102,286 shares in the company, valued at approximately $1,017,746.MannKind Corporation (NASDAQ:MNKD) weekly performance is 15.51%. On last trading day company shares ended up $10.28. Analysts mean target price for the company is $8.58. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 50.10%.
Incyte Corporation (NASDAQ:INCY) CFO David C. Hastings sold 200,000 shares of the stock on the open market in a transaction dated Thursday, June 5th. The shares were sold at an average price of $52.73, for a total transaction of $10,546,000.00. Following the completion of the transaction, the chief financial officer now directly owns 8,500 shares of the company’s stock, valued at approximately $448,205.Incyte Corporation (NASDAQ:INCY) shares fell -1.55% in last trading session and ended the day on $52.16. INCY gross Margin is 99.80% and its return on assets is -23.60%.Incyte Corporation (NASDAQ:INCY) quarterly performance is -18.96%.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Director William R. Keller sold 3,425 shares of the company’s stock on the open market in a transaction dated Thursday, June 5th. The shares were sold at an average price of $170.00, for a total transaction of $582,250.00. Following the sale, the director now directly owns 12,276 shares in the company, valued at approximately $2,086,920. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares moved up 0.41% in last trading session and was closed at $170.20, while trading in range of $167.17 – $172.50. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) year to date (YTD) performance is 28.09%.
Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) SVP Kirk Maples sold 1,500 shares of the stock on the open market in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $14.15, for a total value of $21,225.00. Following the completion of the transaction, the senior vice president now directly owns 1,620 shares of the company’s stock, valued at approximately $22,923.Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) ended the last trading day at $15.57. Company weekly volatility is calculated as 5.18% and price to cash ratio as 4.94.Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) showed a positive weekly performance of 15.33%.
Prothena Corporation PLC (NASDAQ:PRTA) Insider Karin L. Walker sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $21.58, for a total value of $172,640.00. Prothena Corporation PLC (NASDAQ:PRTA) net profit margin is -43.40% and weekly performance is 4.61%. On last trading day company shares ended up $21.78. Prothena Corporation PLC (NASDAQ:PRTA) distance from 50-day simple moving average (SMA50) is -18.76%.